Bio-Rad Laboratories Balance Sheet Health
Financial Health criteria checks 5/6
Bio-Rad Laboratories has a total shareholder equity of $6.8B and total debt of $1.2B, which brings its debt-to-equity ratio to 17.6%. Its total assets and total liabilities are $9.7B and $2.9B respectively. Bio-Rad Laboratories's EBIT is $366.2M making its interest coverage ratio -10.3. It has cash and short-term investments of $1.6B.
Key information
17.6%
Debt to equity ratio
US$1.19b
Debt
| Interest coverage ratio | -10.3x |
| Cash | US$1.62b |
| Equity | US$6.78b |
| Total liabilities | US$2.91b |
| Total assets | US$9.69b |
Recent financial health updates
We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
Sep 08
Bio-Rad Laboratories (NYSE:BIO) Has A Pretty Healthy Balance Sheet
Apr 18Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?
Nov 20We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
Aug 21Does Bio-Rad Laboratories (NYSE:BIO) Have A Healthy Balance Sheet?
May 23Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?
Feb 10Recent updates
We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
Sep 08Bio-Rad Laboratories, Inc.'s (NYSE:BIO) Shares May Have Run Too Fast Too Soon
Jul 18Bio-Rad: Economics Unsupportive With Capital Valued 70 Cents On The Dollar
Jul 14Bio-Rad Laboratories (NYSE:BIO) Has A Pretty Healthy Balance Sheet
Apr 18Bio-Rad: A Lackluster Picks-And-Shovels Life Science Company With A Key Investment Kicker
Apr 14At US$325, Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Worth Looking At Closely?
Feb 07Are Investors Undervaluing Bio-Rad Laboratories, Inc. (NYSE:BIO) By 43%?
Dec 17Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?
Nov 20Bio-Rad: Business Returns Aren't Economically Valuable, Sartorius Now A Hindrance
Oct 25At US$358, Is It Time To Put Bio-Rad Laboratories, Inc. (NYSE:BIO) On Your Watch List?
Oct 02We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
Aug 21Bio-Rad: A Cash Flow Returns On Investments Analysis
Aug 10Are Bio-Rad Laboratories, Inc. (NYSE:BIO) Investors Paying Above The Intrinsic Value?
Jul 30Is It Too Late To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?
Jul 04Does Bio-Rad Laboratories (NYSE:BIO) Have A Healthy Balance Sheet?
May 23A Look At The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
May 01Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching
Apr 04Bio-Rad Labs reports Q4 2022 results
Feb 16Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?
Feb 10Calculating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Jan 20Bio-Rad: How Efficient Is Its Capital Management? A Deep Look, With Technicals
Jan 04Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching
Dec 08Bio-Rad Labs Non-GAAP EPS of $2.60 misses by $0.17, revenue of $680.8M misses by $1.9M
Oct 27A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Oct 14Will Bio-Rad And Qiagen Merge? I Can't See Any Logic To This Deal
Oct 12Bio-Rad Laboratories hits 52-week low; down 40% YTD
Sep 19Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?
Sep 02Bio-Rad Labs Non-GAAP EPS of $3.38 beats by $0.67, revenue of $691.1M beats by $26.5M
Jul 28When Should You Buy Bio-Rad Laboratories, Inc. (NYSE:BIO)?
Jul 25Estimating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Jul 04Bio-Rad Laboratories (NYSE:BIO) Has A Rock Solid Balance Sheet
May 02Financial Position Analysis
Short Term Liabilities: BIO's short term assets ($3.1B) exceed its short term liabilities ($487.0M).
Long Term Liabilities: BIO's short term assets ($3.1B) exceed its long term liabilities ($2.4B).
Debt to Equity History and Analysis
Debt Level: BIO has more cash than its total debt.
Reducing Debt: BIO's debt to equity ratio has increased from 7.8% to 17.6% over the past 5 years.
Debt Coverage: BIO's debt is well covered by operating cash flow (29.1%).
Interest Coverage: BIO earns more interest than it pays, so coverage of interest payments is not a concern.